Is translational research compatible with preclinical publication strategies?

被引:5
|
作者
Linder, Stig [1 ]
Shoshan, Maria C. [1 ]
机构
[1] Karolinska Hosp & Inst, Canc Ctr Karolinska, Dept Pathol & Oncol, S-17176 Stockholm, Sweden
关键词
Imatinib; Translational Research; Mouse Fibroblast; Betulinic Acid; Replicative Senescence;
D O I
10.1186/1748-717X-1-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The term "translational research" is used to describe the transfer of basic biological knowledge into practical medicine, a process necessary for motivation of public spending. In the area of cancer therapeutics, it is becoming increasingly evident that results obtained in vitro and in animal models are difficult to translate into clinical medicine. We here argue that a number of factors contribute to making the translation process inefficient. These factors include the use of sensitive cell lines and fast growing experimental tumors as targets for novel therapies, and the use of unrealistic drug concentrations and radiation doses. We also argue that aggressive interpretation of data, successful in hypothesis-building biological research, does not form a solid base for development of clinically useful treatment modalities. We question whether "clean" results obtained in simplified models, expected for publication in high-impact journals, represent solid foundations for improved treatment of patients. Open-access journals such as Radiation Oncology have a large mission to fulfill by publishing relevant data to be used for making actual progress in translational cancer research.
引用
收藏
页数:3
相关论文
共 50 条
  • [1] Is translational research compatible with preclinical publication strategies?
    Stig Linder
    Maria C Shoshan
    [J]. Radiation Oncology, 1
  • [2] Mapping strategies towards improved external validity in preclinical translational research
    Carneiro, Clarissa F. D.
    Drude, Natascha
    Huelsemann, Maren
    Collazo, Anja
    Toelch, Ulf
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2023, 18 (11) : 1273 - 1285
  • [3] Preclinical research strategies for newly approved drugs as reflected in early publication patterns
    Ursula Köster
    Ingo Nolte
    Martin C. Michel
    [J]. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389 : 187 - 199
  • [4] Preclinical research strategies for newly approved drugs as reflected in early publication patterns
    Koster, Ursula
    Nolte, Ingo
    Michel, Martin C.
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2016, 389 (02) : 187 - 199
  • [5] Preclinical Research Strategies for Newly Approved Veterinary Drugs as Reflected in Early Publication Patterns
    Koester, Ursula
    Nolte, Ingo
    Michel, Martin C.
    [J]. FASEB JOURNAL, 2016, 30
  • [6] Preclinical models for translational sarcoma research
    Hamacher, Rainer
    Bauer, Sebastian
    [J]. CURRENT OPINION IN ONCOLOGY, 2017, 29 (04) : 275 - 285
  • [7] International Conference on Translational Research and Preclinical Strategies in Radio-Oncology (ICTR) - Conference summary
    Coleman, CN
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 49 (02): : 301 - 309
  • [8] Mouse Modeling in oncologic preclinical and translational research
    Carver, Brett S.
    Pandolfi, Pier P.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (18) : 5305 - 5311
  • [9] Preclinical Trials - An Update on Translational Research in ALS
    Ludolph, Albert C.
    Sperfeld, A-D
    [J]. NEURODEGENERATIVE DISEASES, 2005, 2 (3-4) : 215 - 219
  • [10] Preclinical Research - Seal of Approval for translational Medicine
    Herrmann, Sven
    Pichler, Bernd
    Kotzerke, Joerg
    [J]. NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2013, 52 (06): : 205 - 206